Abstract
Introducing biologic treatment in the therapeutic schemes for paediatric patients with inflammatory bowel diseases was a crucial breakthrough in paediatric gastroenterology. Currently, there are two biologic treatment preparations with anti-TNF effects available on the market in the Czech Republic: infliximab (Remicade) and its fully humanised variant adalimumab (Humira).
Efficacy of both these drugs was proven in randomized controlled clinical trials and both drugs have a very good safety profile. Biologic treatment should be administered to children in centres for biologic therapy, where the staff are aware of indication criteria and are experienced enough in optimisation strategies of the therapeutic scheme.